Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  4/20/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
A Phase 1 Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 4/20/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Greater Arkansas Veterans Healthcare
mi
from
Little Rock, AR
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Greater Arkansas Veterans Healthcare
mi
from
Little Rock, AR
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
UCLA
mi
from
Los Angeles, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Palo Alto Veterans Institute for Research
mi
from
Palo Alto, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Palo Alto Veterans Institute for Research
mi
from
Palo Alto, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Stanford University
mi
from
Stanford, CA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Georgetown University Hospital
mi
from
Washington,
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Tampa General Hospital
mi
from
Tampa, FL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Northwestern University
mi
from
Chicago, IL
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Albany Medical Center
mi
from
Albany, NY
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Albany Medical Center
mi
from
Albany, NY
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Mount Sinai Hospital
mi
from
New York, NY
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Albert Einstein Healthcare
mi
from
Philadelphia, PA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Albert Einstein Healthcare
mi
from
Philadelphia, PA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
MUSC Medical Center (Medical University of South Carolina)
mi
from
Charleston, SC
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
MUSC Medical Center (Medical University of South Carolina)
mi
from
Charleston, SC
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
UT Health and Science Center
mi
from
San Antonio, TX
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
UT Health and Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
University Hospitals K.U. Leuven (Dept of Hematology)
mi
from
Leuven,
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
University Hospitals K.U. Leuven (Dept of Hematology)
mi
from
Leuven,
Click here to add this to my saved trials
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2018
Tuscon Medical Center
mi
from
Tucson, AZ
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Phase 3 Prospective, Randomized, Blinded, and Controlled Investigation of HepaSphere/QuadraSphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2018
Tuscon Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
Status: Enrolling
Updated:  4/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
Trans-Rectal Placement of Prostatic Fiducial Markers Under MR-Guidance in Patients Receiving External Beam Radiotherapy for Prostate Cancer: A Pilot Study
Status: Enrolling
Updated: 4/20/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Status: Enrolling
Updated:  4/22/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
Status: Enrolling
Updated: 4/22/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Status: Enrolling
Updated:  4/22/2018
Kimmel Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Status: Enrolling
Updated: 4/22/2018
Kimmel Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Status: Enrolling
Updated:  4/22/2018
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
mi
from
Washington,
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin
Status: Enrolling
Updated: 4/22/2018
Kimmel Cancer Center at Johns Hopkins at Sibley Memorial Hospital
mi
from
Washington,
Click here to add this to my saved trials
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated:  4/22/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
A Phase I Study Of Weekly Taxotere (Docetaxel) And Gleevec (STI571, Imatinib Mesylate, CGP 57148B) In Locally Advanced Or Metastatic Breast Cancer
Status: Enrolling
Updated: 4/22/2018
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated:  4/23/2018
Yale Cancer Center
mi
from
New Haven, CT
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated: 4/23/2018
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated:  4/23/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
An Open Label Randomized Phase II Study of SOM230 and Everolimus in Castrate-Resistant, Chemotherapy-Naïve Prostate Cancer Patients
Status: Enrolling
Updated: 4/23/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Athens, OH
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Athens, OH
Click here to add this to my saved trials
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Gallipolis, OH
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Gallipolis, OH
Click here to add this to my saved trials
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Logan, OH
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Logan, OH
Click here to add this to my saved trials
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated:  4/23/2018
Clinical Research Facility
mi
from
Pomeroy, OH
Community Awareness, Resources and Education (CARE II): Project 3
Community Awareness, Resources and Education (CARE II): Project 3
Status: Enrolling
Updated: 4/23/2018
Clinical Research Facility
mi
from
Pomeroy, OH
Click here to add this to my saved trials
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Status: Enrolling
Updated:  4/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Status: Enrolling
Updated: 4/23/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
New York University
mi
from
New York, NY
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
New York University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Providence Cancer Center
mi
from
Portland, OR
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Providence Cancer Center
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated:  4/23/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Status: Enrolling
Updated: 4/23/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Cancer Care Center of Southern Indiana
mi
from
Bloomington, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
IU Health Central Indiana Cancer Centers
mi
from
Indianapolis, IN
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Metro Health Cancer Care
mi
from
Wyoming, MI
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Metro Health Cancer Care
mi
from
Wyoming, MI
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Nebraska Cancer Specialists
mi
from
Omaha, NE
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
mi
from
New York, NY
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
MUSC Hollings Cancer Center
mi
from
Charleston, SC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
MUSC Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
University of Texas Medical Branch
mi
from
Galveston, TX
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated:  4/23/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147
Status: Enrolling
Updated: 4/23/2018
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/23/2018
Massachusetts General Hospital
mi
from
Boston, MA
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/23/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/23/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/23/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/23/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
STA-9090 in Patients With Advanced Hepatocellular Cancer
A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/23/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials